Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
002821.SZ
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
+45%
1.57
vs 1.08
Q1.23
+59%
1.72
vs 1.08
Q2.23
-38%
2.93
vs 4.72
Q3.23
-46%
1.45
vs 2.71
Q4.23
N/A
0.16
vs NA
Q1.24
-56%
0.76
vs 1.72
Q2.24
-78%
0.64
vs 2.93
Q3.24
-58%
0.61
vs 1.45
Q4.24
+325%
0.68
vs 0.16
Q1.25
+17%
0.89
vs 0.76
Sales Growth
YoY
Current
Estimates
Q2.23
-20%
2.4B vs 3B
Q3.23
-36%
1.8B vs 2.8B
Q4.23
NA
1.4B vs NA
Q1.24
-40%
1.4B vs 2.2B
Q2.24
-46%
1.3B vs 2.4B
Q3.24
-18%
1.4B vs 1.8B
Q4.24
+17%
1.7B vs 1.4B
Q1.25
+13%
1.5B vs 1.4B
Q2.25
+24%
1.6B vs 1.3B
Q3.25
+18%
1.7B vs 1.4B
Return on Equity
QoQ
Q2.23
+6%
0.06
vs 0.04
Q3.23
+3%
0.03
vs 0.06
Q4.23
+0%
0
vs 0.03
Q1.24
+2%
0.02
vs 0
Q2.24
+1%
0.01
vs 0.02
Q3.24
+1%
0.01
vs 0.01
Q4.24
+1%
0.01
vs 0.01
Q1.25
+2%
0.02
vs 0.01
Institutionnal Ownership
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
SHZ
8.86Â ( 10.00%)
Relative Strenght
Volume Buzz
131%
Earning Acce
Yes
Dist 52w H.
0%Quote Panel
Key Metrics
Relative Strength
002821.SZ
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
386%2026-Revenue
305%2026-EPS
597%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 002821.SZ compares to sector?